The newly established Graduate Institute of Health and Biotechnology Law is an expression of Taipei Medical University (TMU)’s expanding commitment to interdisciplinary studies. Faculty research focuses on translational medicine legal policy, venture capital and intangible assets financing, pharmaceutical legal policy, public health law, biotechnology law, as well as food and drug regulation. Our faculty also regularly publish in peer-reviewed journals, deliver invited talks at international conferences, and undertake government research projects, including: Constructing a Legal Framework for Promotion of Taiwan's Vaccine Industry In Order To Anticipate Pandemics and Empirical Studies on the Disputes Pertaining to the Second-Generation of National Health Insurance. Both initiatives will have long-term influence on public health policy-making in Taiwan.
Pedagogical objectives of the Institute include equipping future lawyers and legal experts with knowledge necessary to address medical, public health, and issues related to bio-technology. Courses offered currently include: Medical Law, Biotechnology Law, Health Insurance Law and Patent Law. An especially distinctive component of our curriculum is Introduction to Biomedical Science (for those who do not possess a degree in related fields). Moreover, Research Methods & Legal Writing are also essential components of the Curriculum. The Institute also offers courses relevant to biomedical research and commercialization, such as Intellectual Property and Finance. About half of our courses are offered in conjunction with other TMU departments or with collaborating universities.
Our graduate students are involved in a number of academic projects, including a newly established BioLaw Newsletter and a National Health Insurance Legal Study Group. Both organizations hold regular events and publish up-to-date legal analyses of biomedical innovations.
